Insider Trading Alert - CIEN, MNTA And VLGEA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 15, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $1,771,500.00.

Highlighted Stocks Traded by Insiders:

Ciena (CIEN) - FREE Research Report

Alexander Stephen B, who is Sr VP Chief Technology Officer at Ciena, sold 3,500 shares at $25.39 on June 15, 2015. Following this transaction, the Sr VP Chief Technology Officer owned 148,734 shares meaning that the stake was reduced by 2.3% with the 3,500-share transaction.

Claflin Bruce L., who is Director at Ciena, sold 400 shares at $25.33 on June 15, 2015. Following this transaction, the Director owned 61,762 shares meaning that the stake was reduced by 0.64% with the 400-share transaction.

The shares most recently traded at $25.76, up $0.43, or 1.67% since the insider transaction. Historical insider transactions for Ciena go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 42,010
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 80,527

The average volume for Ciena has been 3.1 million shares per day over the past 30 days. Ciena has a market cap of $3.0 billion and is part of the technology sector and telecommunications industry. Shares are up 32.1% year-to-date as of the close of trading on Monday.

Ciena Corporation provides equipment, software, and services that support the transport, switching, aggregation, service delivery, and management of voice, video, and data traffic on communications networks worldwide. Currently, there are 12 analysts who rate Ciena a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CIEN - FREE

TheStreet Quant Ratings rates Ciena as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Ciena Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Franken Michael, who is President, Biosimilars Busines at Momenta Pharmaceuticals, sold 512 shares at $22.37 on June 15, 2015. Following this transaction, the President, Biosimilars Busines owned 39,001 shares meaning that the stake was reduced by 1.3% with the 512-share transaction.

The shares most recently traded at $22.80, up $0.43, or 1.89% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 7,828
  • 12-Week # shares sold: 90,134
  • 24-Week # shares sold: 159,362

The average volume for Momenta Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 88.62% year-to-date as of the close of trading on Monday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 5 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 6,015 shares at $30.24 on June 15, 2015. Following this transaction, the Shareholder owned 946,520 shares meaning that the stake was reduced by 0.63% with the 6,015-share transaction.

The shares most recently traded at $30.32, up $0.08, or 0.28% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 43,446
  • 12-Week # shares sold: 158,791
  • 24-Week # shares sold: 244,183

The average volume for Village Super Market has been 36,500 shares per day over the past 30 days. Village Super Market has a market cap of $297.5 million and is part of the services sector and retail industry. Shares are up 10.85% year-to-date as of the close of trading on Monday.

Village Super Market, Inc., together with its subsidiaries, operates a chain of supermarkets in the United States. The stock currently has a dividend yield of 3.3%. The company has a P/E ratio of 14.4. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Stocks Rise Sharply, Facebook Ignites a Nasdaq Rally

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations